<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40511773</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Venous Thromboembolism Prophylaxis Practice Patterns, Outcomes, and Risk Stratification After Surgery for IBD: A National Surgical Quality Improvement Program IBD Collaborative Study.</ArticleTitle><Pagination><StartPage>1062</StartPage><EndPage>1073</EndPage><MedlinePgn>1062-1073</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003833</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The optimal venous thromboembolism chemoprophylaxis strategy after surgery for IBD is not defined.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the real-world efficacy of chemoprophylaxis strategies after surgery for IBD in a retrospective cohort.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective analysis of medical records from the National Surgical Quality Improvement Program IBD Collaborative of patients treated between July 2020 to October 2023.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Seventeen medical centers.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with IBD undergoing colectomy and/or proctectomy were included.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Chemoprophylaxis.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Thirty-day venous thromboembolism (clot) rates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During 3 years, 1797 patients were eligible for chemoprophylaxis and included in the analysis, of whom 44 (2.4%) developed a clot within 30 days: 50% before and after discharge, respectively. Clots were diagnosed a median of 9 days postoperatively. The most common clots were portomesenteric (39%), pulmonary embolism (27%), and upper extremity (18%). Before discharge, clot rates differed by chemoprophylaxis strategy: enoxaparin (0.57%) versus unfractionated heparin (2.1%, p = 0.006). Any extended chemoprophylaxis was used in 50.5%, and clot rates differed by strategy: no extended chemoprophylaxis (1.4%), enoxaparin (0.63%), and others (3.5%, p = 0.01). Chemoprophylaxis strategies were not associated with bleeding complications. Multivariable analysis revealed that preoperative systemic inflammatory response syndrome ( p = 0.0005) and extended resections ( p &lt; 0.0001) were independent risk factors for postoperative clots. Patients with 0, 1, or 2 risk factors had clot rates of 1.2%, 4.0%, and 13.5%, respectively ( p &lt; 0.0001). Inpatient and extended prophylaxis with enoxaparin were independently associated with a lower risk of clots both before and after discharge ( p = 0.002 and p = 0.02, respectively), with relative risk reductions of 74.8% and 72.6%. For a clot rate of 2.5%, the estimated number needed to treat with enoxaparin in-hospital and postdischarge was 54 and 55 patients, respectively.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The limitations to this study were generalizability and selection bias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">After IBD surgery, venous thromboembolism chemoprophylaxis with enoxaparin was associated with a decreased risk of clot formation before and after discharge. Patients at highest risk may benefit the most from extended chemoprophylaxis. See Video Abstract .</AbstractText><AbstractText Label="PATRONES DE PRCTICA, RESULTADOS Y ESTRATIFICACIN DEL RIESGO EN LA PROFILAXIS DE LA TROMBOEMBOLIA VENOSA TRAS CIRUGA POR ENFERMEDAD INFLAMATORIA INTESTINAL ESTUDIO COLABORATIVO DEL PROGRAMA NACIONAL DE MEJORA DE LA CALIDAD QUIRRGICA SOBRE EII" NlmCategory="UNASSIGNED">ANTECEDENTES:No se ha definido la estrategia &#xf3;ptima de quimioprofilaxis de la tromboembolia venosa tras la cirug&#xed;a por enfermedad inflamatoria intestinal.OBJETIVO:Investigar la eficacia real de las estrategias de quimioprofilaxis tras la cirug&#xed;a por enfermedad inflamatoria intestinal en una cohorte retrospectiva.DISE&#xd1;O:Entre julio de 2020 y octubre de 2023, la Colaboraci&#xf3;n sobre Enfermedad Inflamatoria Intestina deel Programa Nacional de Mejora de la Calidad Quir&#xfa;rgica.ENTORNO:Diecisiete centros m&#xe9;dicos.PACIENTES:Pacientes con enfermedad inflamatoria intestinal sometidos a colectom&#xed;a y/o proctectom&#xed;a.INTERVENCIONES:Quimioprofilaxis.PRINCIPALES MEDIDAS DE RESULTADO:Tasas de tromboembolia venosa (co&#xe1;gulos) a 30 d&#xed;as.RESULTADOS:Durante tres a&#xf1;os, 1797 pacientes fueron elegibles para quimioprofilaxis y fueron analizados, de los cuales 44 (2.4 %) desarrollaron un co&#xe1;gulo en un plazo de 30 d&#xed;as: el 50 % antes y despu&#xe9;s del alta, respectivamente. Los co&#xe1;gulos se diagnosticaron una mediana de 9 d&#xed;as despu&#xe9;s de la operaci&#xf3;n. Los co&#xe1;gulos m&#xe1;s frecuentes fueron portomesent&#xe9;ricos (39 %), embolia pulmonar (27 %) y extremidades superiores (18 %). Antes del alta, las tasas de co&#xe1;gulos difirieron seg&#xfa;n la estrategia de quimioprofilaxis: enoxaparina (0.57 %) frente a heparina no fraccionada (2.1 %), p = 0.006. Se utiliz&#xf3; una quimioprofilaxis prolongada en el 50.5 % de los casos y las tasas de co&#xe1;gulos difirieron seg&#xfa;n la estrategia: sin quimioprofilaxis prolongada (1.4 %), enoxaparina (0.63 %) y otras (3.5 %) p = 0.01. Las estrategias de quimioprofilaxis no se asociaron con complicaciones hemorr&#xe1;gicas. El an&#xe1;lisis multivariable revel&#xf3; que el s&#xed;ndrome de respuesta inflamatoria sist&#xe9;mica preoperatoria ( p = 0.0005) y las resecciones extendidas ( p &lt; 0.0001) eran factores de riesgo independientes para los co&#xe1;gulos postoperatorios. Los pacientes con 0, 1 o 2 factores de riesgo tuvieron tasas de co&#xe1;gulos del 1.2 %, 4.0 % y 13.5 %, respectivamente ( p &lt; 0.0001). La profilaxis hospitalaria y prolongada con enoxaparina se asoci&#xf3; de forma independiente con un menor riesgo de co&#xe1;gulos antes y despu&#xe9;s del alta ( p = 0.002 y p = 0.02, respectivamente), con reducciones del riesgo relativo del 74.8 % y el 72.6 %. Para una tasa de co&#xe1;gulos del 2.5 %, el n&#xfa;mero estimado de pacientes que deb&#xed;an recibir tratamiento con enoxaparina durante la hospitalizaci&#xf3;n y despu&#xe9;s del alta fue de 54 y 55, respectivamente.LIMITACIONES:Generalizaci&#xf3;n; sesgo de selecci&#xf3;n.CONCLUSIONES:Tras la cirug&#xed;a por enfermedad inflamatoria intestinal, la quimioprofilaxis de la tromboembolia venosa con enoxaparina se asoci&#xf3; con una disminuci&#xf3;n del riesgo de co&#xe1;gulos antes y despu&#xe9;s del alta. Los pacientes con mayor riesgo pueden beneficiarse m&#xe1;s de una quimioprofilaxis prolongada. (Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holubar</LastName><ForeName>Stefan D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0002-2549-9042</Identifier><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenstein</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2646-0625</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of California, San Diego School of Medicine, La Jolla, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordeianou</LastName><ForeName>Liliana G</ForeName><Initials>LG</Initials><Identifier Source="ORCID">0000-0003-3418-6774</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Massachusetts General Hospital, Colorectal Surgery Program, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>William C</ForeName><Initials>WC</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowell</LastName><ForeName>Kristen T</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0002-9138-186</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davids</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hrabe</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Justiniano</LastName><ForeName>Carla F</ForeName><Initials>CF</Initials><Identifier Source="ORCID">0000-0002-9526-0643</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Cincinnati, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Muneera R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0382-880</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kin</LastName><ForeName>Cindy J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0001-8273-9471</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Stanford Health Care, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krane</LastName><ForeName>Mukta K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0003-4872-1061</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Washington Medical Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Albany Medical Center, Albany, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olortegui</LastName><ForeName>Kinga S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poylin</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5814-3915</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0003-2014-0302</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scow</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-4010-5275</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Penn State Health, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plietz</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Mount Sinai Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NSQIP IBD Collaborative</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017984">Enoxaparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058996" MajorTopicYN="N">Quality Improvement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017984" MajorTopicYN="N">Enoxaparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="Y">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018890" MajorTopicYN="N">Chemoprevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemoprophylaxis</Keyword><Keyword MajorTopicYN="N">Colectomy</Keyword><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Direct oral anticoagulants</Keyword><Keyword MajorTopicYN="N">IBD</Keyword><Keyword MajorTopicYN="N">Ileoanal pouch</Keyword><Keyword MajorTopicYN="N">Low-molecular-weight heparin</Keyword><Keyword MajorTopicYN="N">Proctectomy</Keyword><Keyword MajorTopicYN="N">Ulcerative colitis</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Anzlovar</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Batten</LastName><ForeName>JoAnn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belding-Schmitt</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bordeianou</LastName><ForeName>Liliana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohne</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chapman</LastName><ForeName>Will</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Lynne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crowell</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davids</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Leon</LastName><ForeName>Elmer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deutsch</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devaney</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Divino</LastName><ForeName>Celia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Du</LastName><ForeName>Austin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eisenstein</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Germaine</LastName><ForeName>Odile</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goyette</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hilbert</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirbe</LastName><ForeName>Mitzi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holubar</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hrabe</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huggins</LastName><ForeName>Pam</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyke</LastName><ForeName>Roxanne</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Justiniano</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Muneera</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keenan</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khaitov</LastName><ForeName>Sergey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kin</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kunitake</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lavryk</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liska</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Messaris</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Reba</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mutch</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Narsule</LastName><ForeName>Chaitan</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olortegui</LastName><ForeName>Kinga</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paquette</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paredes</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plietz</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poylin</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prachand</LastName><ForeName>Vivek</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramamoorthy</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ricciardi</LastName><ForeName>Rocco</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenkranz</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sansone</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scow</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Radhika</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spain</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinhagen</LastName><ForeName>Randolph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strong</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sylla</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Anila</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Valora</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomaska</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torbela</LastName><ForeName>Aimee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valerian</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whyte</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>8</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40511773</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003833</ArticleId><ArticleId IdType="pii">00003453-990000000-00977</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brady MT, Patts GJ, Rosen A, et al. Postoperative venous thromboembolism in patients undergoing abdominal surgery for IBD: a common but rarely addressed problem. Dis Colon Rectum. 2017;60:61&#x2013;67.</Citation></Reference><Reference><Citation>GamalEldin M, DeHaan RK, Sklow B, et al. Portomesenteric venous thrombosis after colorectal surgery for inflammatory bowel disease: a call to action? [ASCRS abstract POD232]. Dis Colon Rectum. 2021;64:e109&#x2013;e364.</Citation></Reference><Reference><Citation>McKenna NP, Bews KA, Behm KT, Mathis KL, Cima RR, Habermann EB. Timing and location of venous thromboembolisms after surgery for inflammatory bowel disease. J Surg Res. 2024;296:563&#x2013;570.</Citation></Reference><Reference><Citation>Wallaert JB, De Martino RR, Marsicovetere PS, et al. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum. 2012;55:1138&#x2013;1144.</Citation></Reference><Reference><Citation>Bergqvist D, Agnelli G, Cohen AT, et al.; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975&#x2013;980.</Citation></Reference><Reference><Citation>Fleming F, Gaertner W, Ternent CA, et al. The American Society of Colon and Rectal Surgeons clinical practice guideline for the prevention of venous thromboembolic disease in colorectal surgery. Dis Colon Rectum. 2018;61:14&#x2013;20.</Citation></Reference><Reference><Citation>Eisenstein S, Holubar SD, Hilbert N, et al. The ACS National Surgical Quality Improvement Program-Inflammatory Bowel Disease Collaborative: design, implementation, and validation of a disease-specific module. Inflamm Bowel Dis. 2019;25:1731&#x2013;1739.</Citation></Reference><Reference><Citation>Greaves SW, Holubar SD. Preoperative hospitalization is independently associated with increased risk for venous thromboembolism in patients undergoing colorectal surgery: a national surgical quality improvement program database study. Dis Colon Rectum. 2015;58:782&#x2013;791.</Citation></Reference><Reference><Citation>McKenna NP, Bews KA, Behm KT, Mathis KL, Lightner AL, Habermann EB. Do patients with inflammatory bowel disease have a higher postoperative risk of venous thromboembolism or do they undergo more high-risk operations? Ann Surg. 2020;271:325&#x2013;331.</Citation></Reference><Reference><Citation>Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17(suppl 3):304&#x2013;312.</Citation></Reference><Reference><Citation>Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632&#x2013;634.</Citation></Reference><Reference><Citation>Benlice C, Holubar SD, Gorgun E, et al. Extended venous thromboembolism prophylaxis after elective surgery for IBD patients: nomogram-based risk assessment and prediction from nationwide cohort. Dis Colon Rectum. 2018;61:1170&#x2013;1179.</Citation></Reference><Reference><Citation>Cheong JY, Connelly TM, Russell T, et al. Venous thromboembolism risk stratification for patients undergoing surgery for IBD using a novel six factor scoring system using NSQIP-IBD registry. ANZ J Surg. 2023;93:1620&#x2013;1625.</Citation></Reference><Reference><Citation>Cordell WH. Number needed to treat (NNT). Ann Emerg Med. 1999;33:433&#x2013;436.</Citation></Reference><Reference><Citation>Montero Ruiz E, Baldominos Utrilla G, L&#xf3;pez &#xc1;lvarez J, Santolaya Perrin R. Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients. Thromb Res. 2011;128:440&#x2013;445.</Citation></Reference><Reference><Citation>Fagarasanu A, Alotaibi GS, Hrimiuc R, Lee AY, Wu C. Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23:1422&#x2013;1430.</Citation></Reference><Reference><Citation>Lee CHA, Jia X, Lipman JM, et al. Defining the economic burden of perioperative venous thromboembolism in inflammatory bowel disease in the United States. Dis Colon Rectum. 2021;64:871&#x2013;880.</Citation></Reference><Reference><Citation>Leeds IL, DiBrito SR, Canner JK, Haut ER, Safar B. Cost-benefit limitations of extended, outpatient venous thromboembolism prophylaxis following surgery for Crohn&#x2019;s disease. Dis Colon Rectum. 2019;62:1371&#x2013;1380.</Citation></Reference><Reference><Citation>Leeds IL, Haut ER. Are we really supposed to start giving venous thromboembolism prophylaxis for a month after outpatient surgery? JAMA Surg. 2019;154:1133.</Citation></Reference><Reference><Citation>Prien C, Ribakow D, Steele SR, et al. What about patient cost? Defining copay and out-of-pocket costs of extended venous thromboembolism chemoprophylaxis after colorectal surgery. J Gastrointest Surg. 2023;27:152&#x2013;154.</Citation></Reference><Reference><Citation>Stewart KT, Jafari H, Pattillo J, et al. Avoiding the needle: a quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery. Gynecol Oncol. 2024;188:131&#x2013;139.</Citation></Reference><Reference><Citation>Ogilvie JW Jr, Khan MT, Hayakawa E, Parker J, Luchtefeld MA. Low-dose rivaroxaban as extended prophylaxis reduces postdischarge venous thromboembolism in patients with malignancy and IBD. Dis Colon Rectum. 2024;67:457&#x2013;465.</Citation></Reference><Reference><Citation>Holubar SD, Eisenstein S, Bordeianou L, et al. Venous thromboembolism prophylaxis practice patterns, outcomes, and risk stratification after surgery for inflammatory bowel disease: a NSQIP IBD Collaborative study. Dis Colon Rectum. 2025;68:e228&#x2013;e229.</Citation></Reference><Reference><Citation>Cordova-Cassia C, Wong D, Cotter MB, Cataldo TE, Poylin VY. Patient&#x2019;s compliance is a contributor to failure of extended antithrombotic prophylaxis in colorectal surgery: prospective cohort study. Surg Endosc. 2022;36:267&#x2013;273.</Citation></Reference><Reference><Citation>Elzaafarany A, Tawfik A, Igbekele T, Day A. EP-351 Extended VTE prophylaxis in patients undergoing elective surgery for colorectal cancer in a district general hospital and its compliance with NICE guidelines. Br J Surg. 2022;109(Suppl 5):znac245.091.</Citation></Reference><Reference><Citation>Yeung T, Ng S, Sidhu R, Ali M. 463 Adherence to extended venous thromboembolism prophylaxis for post operative resection of colorectal malignancies. Br J Surg. 2023;110(Suppl 7):znad258.105.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38902840</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Bowel Dysfunction After Colon Cancer Surgery: A Prospective, Longitudinal, Multicenter Study.</ArticleTitle><Pagination><StartPage>1322</StartPage><EndPage>1331</EndPage><MedlinePgn>1322-1331</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003358</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Longitudinal studies on functional outcomes after colon resection are limited.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate bowel dysfunction and related distress 1 and 3 years after colon resection using the low anterior resection syndrome score as well as specific validated items.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This study presents the long-term results of bowel dysfunction and related distress based on the Quality of Life in Colon Cancer study, an observational, prospective multicenter study of patients with newly diagnosed colon cancer.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">The study was conducted at 21 Swedish and Danish surgical centers between 2015 and 2019.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">All patients who underwent right-sided or left-sided colon resection were considered eligible. Exclusion criteria were age younger than 18 years, cognitive impairment, or inability to understand Swedish/Danish. Patients completed extensive questionnaires at diagnosis and after 1 and 3 years. Clinical data were supplemented by national quality registries.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The low anterior resection syndrome score, specific bowel symptoms, and patient-reported distress were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 1221 patients (83% response rate), 17% reported major low anterior resection syndrome 1 year after either type of resection; this finding was consistent at 3 years (17% right, 16% left). In the long-term, the only significant difference between types of resections was a high occurrence of loose stools after right-sided resections. Overall, less than one-fifth of patients experienced distress, with women reporting more frequent symptoms and greater distress. In particular, incontinence and loose stools correlated strongly with distress.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Absence of prediagnosis bowel function data.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study indicates that bowel function remains largely intact after colon resection, with only a minority reporting significant distress. Adverse outcomes were more common among women. The occurrence of loose stools after right-sided resection and the association between incontinence, loose stools, and distress highlights a need for postoperative evaluations and more thorough assessments beyond the low anterior resection syndrome score when evaluating patients with colon cancer. See the Video Abstract .</AbstractText><AbstractText Label="DISFUNCIONAMIENTO INTESTINAL DESPUS DE LA CIRUGA POR CNCER DE COLON ESTUDIO PROSPECTIVO, LONGITUDINAL Y MULTICNTRICO" NlmCategory="UNASSIGNED">ANTECEDENTES:Los estudios longitudinales sobre el resultado funcional despu&#xe9;s de una resecci&#xf3;n c&#xf3;lica son limitados.OBJETIVO:Examinar la disfunci&#xf3;n intestinal y el malestar relacionado uno y tres a&#xf1;os despu&#xe9;s de la resecci&#xf3;n del colon utilizando la puntuaci&#xf3;n de referencia en el s&#xed;ndrome de resecci&#xf3;n anterior baja (LARS), as&#xed; como otros &#xed;tems de validez espec&#xed;fica.DISE&#xd1;O:Este estudio presenta los resultados a largo plazo de la disfunci&#xf3;n intestinal y la angustia relacionada seg&#xfa;n el estudio QoLiCOL (Quality of Life in COLon cancer), un analisis observacional, prospectivo y multic&#xe9;ntrico de pacientes con c&#xe1;ncer de colon reci&#xe9;n diagnosticado.AJUSTES:El presente estudio fu&#xe9; realizado en 21 centros quir&#xfa;rgicos suecos y daneses entre 2015 y 2019.PACIENTES:Todos los pacientes sometidos a resecci&#xf3;n de colon, tanto del lado derecho como el izquierdo se consideraron elegibles. Los criterios de exclusi&#xf3;n fueron tener menos de 18 a&#xf1;os, deterioro cognitivo o incapacidad para entender sueco/dan&#xe9;s. Los pacientes completaron extensos cuestionarios en el momento del diagn&#xf3;stico y despu&#xe9;s de uno y tres a&#xf1;os. Los datos cl&#xed;nicos se complementaron con los registros de calidad binacionales.PRINCIPALES MEDIDAS DE RESULTADO:Se evaluaron los s&#xed;ntomas intestinales espec&#xed;ficos, la puntuaci&#xf3;n LARS y la angustia manifestada por cada paciente.RESULTADOS:De 1221 pacientes (tasa de respuesta del 83%), el 17% inform&#xf3; LARS mayor un a&#xf1;o despu&#xe9;s de cualquier tipo de resecci&#xf3;n, consistente a los tres a&#xf1;os (17% derecha, 16% izquierda). A largo plazo, la &#xfa;nica diferencia significativa entre los tipos de resecci&#xf3;n fue una alta incidencia de heces liquidas despu&#xe9;s de las resecciones del lado derecho. En general, menos de una quinta parte de los pacientes experimentaron angustia, y fu&#xe9; la poblacion femenina qui&#xe9;n inform&#xf3; de s&#xed;ntomas m&#xe1;s frecuentes y de mayor angustia. En particular, la incontinencia y las heces liquidas se correlacionaron fuertemente con la angustia.LIMITACIONES:Ausencia de datos de funci&#xf3;n intestinal previos al diagn&#xf3;stico.CONCLUSIONES:Nuestro estudio indica que la funci&#xf3;n intestinal permanece en gran medida intacta despu&#xe9;s de la resecci&#xf3;n del colon, y s&#xf3;lo una minor&#xed;a reporta malestar significativo. Los resultados adversos fueron m&#xe1;s comunes en la poblaci&#xf3;n femenina. La aparici&#xf3;n de heces liquidas despu&#xe9;s de la resecci&#xf3;n del lado derecho y la asociaci&#xf3;n entre incontinencia, heces liquidas y malestar resalta la necesidad de evaluaciones postoperatorias y valoraciones m&#xe1;s exhaustivas m&#xe1;s all&#xe1; de la puntuaci&#xf3;n LARS al evaluar a los pacientes con c&#xe1;ncer de colon. (Traducci&#xf3;n-Dr. Xavier Delgadillo ).</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Colon and Rectal Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sandberg</LastName><ForeName>Sofia J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0001-5900-4717</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Scandinavian Surgical Outcomes Research Group, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Region V&#xe4;stra G&#xf6;taland, Sahlgrenska University Hospital/&#xd6;stra, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Scandinavian Surgical Outcomes Research Group, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Region V&#xe4;stra G&#xf6;taland, Sahlgrenska University Hospital/&#xd6;stra, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tasselius</LastName><ForeName>Viktor A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Department of Surgery, Scandinavian Surgical Outcomes Research Group, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angenete</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgery, Scandinavian Surgical Outcomes Research Group, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Region V&#xe4;stra G&#xf6;taland, Sahlgrenska University Hospital/&#xd6;stra, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02530593</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>VGFOUREG-557431, VGFOUREG-644441, VGFOUREG-733172</GrantID><Agency>The Healthcare sub-committee, Region V&#xc3;&#xa4;stra G&#xc3;&#xb6;taland</Agency><Country/></Grant><Grant><GrantID>VR2021-01025, VR2017-01103</GrantID><Agency>the Swedish Research Council</Agency><Country/></Grant><Grant><GrantID>22 2265 Pj, 19 0333 Pj</GrantID><Agency>the Swedish Cancer Society</Agency><Country/></Grant><Grant><GrantID>FB22-64</GrantID><Agency>Assar Gabrielsson foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="Y">Colonic Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005242" MajorTopicYN="N">Fecal Incontinence</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="N">Constipation</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>21</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>20</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38902840</ArticleId><ArticleId IdType="pmc">PMC11373893</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003358</ArticleId><ArticleId IdType="pii">00003453-202410000-00017</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Keane C, Fearnhead NS, Bordeianou LG, et al. ; LARS International Collaborative Group. International consensus definition of low anterior resection syndrome. Dis Colon Rectum. 2020;63:274&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7034376</ArticleId><ArticleId IdType="pubmed">32032141</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryant CL, Lunniss PJ, Knowles CH, Thaha MA, Chan CL. Anterior resection syndrome. Lancet Oncol. 2012;13:e403&#x2013;e408.</Citation><ArticleIdList><ArticleId IdType="pubmed">22935240</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandberg S, Asplund D, Bisgaard T, et al. . Low anterior resection syndrome in a Scandinavian population of patients with rectal cancer: a longitudinal follow-up within the QoLiRECT study. Colorectal Dis. 2020;22:1367&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pubmed">32346917</ArticleId></ArticleIdList></Reference><Reference><Citation>Keane C, Wells C, O&#x2019;Grady G, Bissett IP. Defining low anterior resection syndrome: a systematic review of the literature. Colorectal Dis. 2017;19:713&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">28612460</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkuijl SJ, Jonker JE, Trzpis M, Burgerhof JGM, Broens PMA, Furn&#xe9;e EJB. Functional outcomes of surgery for colon cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2021;47:960&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">33277056</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchli C, Martling A, Sj&#xf6;vall A. Low anterior resection syndrome after right- and left-sided resections for colonic cancer. BJS Open. 2019;3:387&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551391</ArticleId><ArticleId IdType="pubmed">31183455</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen HM, Elfeki H, Emmertsen KJ, Laurberg S. Long-term bowel dysfunction after right-sided hemicolectomy for cancer. Acta Oncol. 2020;59:1240&#x2013;1245.</Citation><ArticleIdList><ArticleId IdType="pubmed">32501750</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen HM, Krogh K, Borre M, et al. . Chronic loose stools following right-sided hemicolectomy for colon cancer and the association with bile acid malabsorption and small intestinal bacterial overgrowth. Colorectal Dis. 2023;25:600&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">36347822</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfeki H, Larsen HM, Emmertsen KJ, et al. . Bowel dysfunction after sigmoid resection for cancer and its impact on quality of life. Br J Surg. 2019;106:142&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">30211443</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkuijl SJ, Furn&#xe9;e EJB, Kelder W, et al. . Long-term bowel dysfunction and decline in quality of life following surgery for colon cancer: call for personalized screening and treatment. Dis Colon Rectum. 2022;65:1531&#x2013;1541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9645552</ArticleId><ArticleId IdType="pubmed">35982522</ArticleId></ArticleIdList></Reference><Reference><Citation>Magdeburg J, Glatz N, Post S, Kienle P, Rickert A. Long-term functional outcome of colonic resections: how much does faecal impairment influence quality of life? Colorectal Dis. 2016;18:O405&#x2013;O413.</Citation><ArticleIdList><ArticleId IdType="pubmed">27647736</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg. 2012;255:922&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pubmed">22504191</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakash RA, Hutton JL, J&#xf8;rstad-Stein EC, Gates S, Lamb SE. Maximising response to postal questionnaires&#x2014;a systematic review of randomised trials in health research. BMC Med Res Methodol. 2006;6:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1421421</ArticleId><ArticleId IdType="pubmed">16504090</ArticleId></ArticleIdList></Reference><Reference><Citation>Moberger P, Sk&#xf6;ldberg F, Birgisson H. Evaluation of the Swedish Colorectal Cancer Registry: an overview of completeness, timeliness, comparability and validity. Acta Oncol. 2018;57:1611&#x2013;1621.</Citation><ArticleIdList><ArticleId IdType="pubmed">30477372</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein MF, G&#xf6;genur I, Ingeholm P, Njor SH, Iversen LH, Emmertsen KJ; DCCG Validation Group. Validation of the Danish Colorectal Cancer Group (DCCG.dk) database&#x2014;on behalf of the Danish Colorectal Cancer Group. Colorectal Dis. 2020;22:2057&#x2013;2067.</Citation><ArticleIdList><ArticleId IdType="pubmed">32894818</ArticleId></ArticleIdList></Reference><Reference><Citation>Steineck G, Helgesen F, Adolfsson J, et al. ; Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347:790&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226149</ArticleId></ArticleIdList></Reference><Reference><Citation>Juul T, Ahlberg M, Biondo S, et al. . International validation of the low anterior resection syndrome score. Ann Surg. 2014;259:728&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">23598379</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing.
Vienna, Austria: R Foundation for Statistical Computing. https://www.R-project.org/. Accessed September 1, 2023.</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>van Heinsbergen M, Van der Heijden JAG, Stassen LP, et al. . The low anterior resection syndrome in a reference population: prevalence and predictive factors in the Netherlands. Colorectal Dis. 2020;22:46&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">31344293</ArticleId></ArticleIdList></Reference><Reference><Citation>Juul T, Elfeki H, Christensen P, Laurberg S, Emmertsen KJ, Bager P. Normative data for the low anterior resection syndrome score (LARS Score). Ann Surg. 2019;269:1124&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">31082911</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulskas A, Kavaliauskas P, Kulikauskas E, et al. . Low anterior resection syndrome: what have we learned assessing a large population? J Clin Med. 2022;11:4752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9410299</ArticleId><ArticleId IdType="pubmed">36012991</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon J, Ehlebracht A, Cwintal M, et al. . Low anterior resection syndrome in a reference North American sample: prevalence and associated factors. J Am Coll Surg. 2023;237:679&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">37466264</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock D, Angenete E, Gonzales E, Heath J, Haglind E. Assessing health, quality of life and urogenital function in a sample of the Swedish general population: a cross-sectional study. BMJ Open. 2018;8:e021974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942440</ArticleId><ArticleId IdType="pubmed">29730632</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut. 1992;33:818&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1379343</ArticleId><ArticleId IdType="pubmed">1624166</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter SA, Kjellstr&#xf6;m L, Nyhlin H, Talley NJ, Agr&#xe9;us L. Assessment of normal bowel habits in the general adult population: the Popcol study. Scand J Gastroenterol. 2010;45:556&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">20205503</ArticleId></ArticleIdList></Reference><Reference><Citation>Yde J, Larsen HM, Laurberg S, Krogh K, Moeller HB. Chronic diarrhoea following surgery for colon cancer-frequency, causes and treatment options. Int J Colorectal Dis. 2018;33:683&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">29589108</ArticleId></ArticleIdList></Reference><Reference><Citation>Hope C, Reilly J, Lund J, Andreyev H. Systematic review: the effect of right hemicolectomy for cancer on postoperative bowel function. Support Care Cancer. 2020;28:4549&#x2013;4559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7447648</ArticleId><ArticleId IdType="pubmed">32430603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohigashi S, Hoshino Y, Ohde S, Onodera H. Functional outcome, quality of life, and efficacy of probiotics in postoperative patients with colorectal cancer. Surg Today. 2011;41:1200&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pubmed">21874415</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38305749</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Assessing Severity of Low Anterior Resection Syndrome After Intersphincteric Resection for Ultralow Rectal Cancer: A Pilot Study Using an Exploratory Instrument.</ArticleTitle><Pagination><StartPage>723</StartPage><EndPage>731</EndPage><MedlinePgn>723-731</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003210</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Delphi consensus identified 8 symptoms and 8 consequences as the highest priorities for defining low anterior resection syndrome.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe an exploratory scoring instrument correlating the Delphi consensus on low anterior resection syndrome with functional and quality-of-life scores following intersphincteric resection for ultralow rectal cancer.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This was a prospective pilot study. In accordance with the Wexner incontinence score, 5 frequency responses ranging from never (score 0) to always (score 4) were used to measure the severity of symptom- and consequence-specific variables.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Colorectal surgery referral center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Among 161 eligible patients, 137 participants (85%) completed an electronic self-assessment survey regarding function and quality of life at scheduled follow-up, including 3 to 6, 12, and &#x2265;24 months after ileostomy reversal.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Outcome measures included patient-reported severity of the identified priorities, and their correlation with condition-specific quality of life.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The most frequent symptom and consequence were "emptying difficulties" and "dissatisfaction with the bowels," respectively. Aside from "emptying difficulties," the proportions of negative symptom domains increased after reversal. In particular, neither the frequency responses nor the severity scores of "emptying difficulties" differed between groups. The percentages of "always" selection for consequence domains improved at 12-month follow-up, whereas a higher rate was observed at 24 months, except for "toilet dependence" and "dissatisfaction with the bowels." We found significant improvements in the summary score of the Fecal Incontinence Quality-of-Life Scale ( p = 0.04) and our exploratory instrument ( p = 0.009) but not in functional scores measured by traditional questionnaires. Furthermore, the condition-specific quality of life strongly correlated with the Delphi consensus severity score ( rs = -0.73).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Single-institution data and limited sample size.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The important priorities identified by the Delphi consensus might enable a comprehensive overview and a better assessment of low anterior resection syndrome after intersphincteric resection. See Video Abstract .</AbstractText><AbstractText Label="EVALE LA GRAVEDAD DEL SNDROME DE RESECCIN ANTERIOR BAJA DESPUS DE LA RESECCIN INTERESFINTRICA PARA EL CNCER DE RECTO ULTRABAJO UN ESTUDIO PILOTO QUE UTILIZA UN INSTRUMENTO EXPLORATORIO" NlmCategory="UNASSIGNED">ANTECEDENTES:El consenso Delphi identific&#xf3; ocho s&#xed;ntomas y ocho consecuencias como las m&#xe1;ximas prioridades para definir el s&#xed;ndrome de resecci&#xf3;n anterior baja.OBJETIVO:Describir un instrumento de puntuaci&#xf3;n exploratorio que correlaciona el consenso Delphi sobre el s&#xed;ndrome de resecci&#xf3;n anterior baja con puntuaciones funcionales y de calidad de vida despu&#xe9;s de la resecci&#xf3;n interesfinteriana para el c&#xe1;ncer de recto ultrabajo.DISE&#xd1;O:Este fue un estudio piloto prospectivo. De acuerdo con la puntuaci&#xf3;n de incontinencia de Wexner, se utilizaron cinco respuestas de frecuencia que van desde nunca (puntuaci&#xf3;n 0) hasta siempre (puntuaci&#xf3;n 4) para medir la gravedad de las variables espec&#xed;ficas de los s&#xed;ntomas y las consecuencias.AJUSTES:Centro de referencia de cirug&#xed;a colorrectal.PACIENTES:Entre 161 pacientes elegibles, 137 (85%) participantes completaron una encuesta electr&#xf3;nica de autoevaluaci&#xf3;n sobre la funci&#xf3;n y la calidad de vida en el seguimiento programado, incluidos 3 a 6, 12 y &#x2265; 24 meses despu&#xe9;s de la reversi&#xf3;n de la ileostom&#xed;a.MEDIDAS PRINCIPALES DE RESULTADO:Las medidas de resultado incluyeron la gravedad de estas prioridades informada por los pacientes, as&#xed; como su correlaci&#xf3;n con la calidad de vida espec&#xed;fica de la afecci&#xf3;n.RESULTADOS:El s&#xed;ntoma y la consecuencia m&#xe1;s frecuentes fueron "dificultades para vaciar" e "insatisfacci&#xf3;n con las deposiciones", respectivamente. Aparte de las "dificultades de vaciado", las proporciones de dominios de s&#xed;ntomas negativos aumentaron despu&#xe9;s de la reversi&#xf3;n. En particular, tanto las respuestas de frecuencia como las puntuaciones de gravedad de las "dificultades para vaciar" no difirieron entre los grupos. Los porcentajes de "opci&#xf3;n siempre" para los dominios de consecuencias mejoraron a los 12 meses de seguimiento, mientras que se observ&#xf3; una tasa m&#xe1;s alta a los 24 meses despu&#xe9;s, excepto para "dependencia del ba&#xf1;o" e "insatisfacci&#xf3;n con los intestinos". Encontramos mejoras significativas en la puntuaci&#xf3;n resumida de la Escala de calidad de vida de incontinencia fecal ( p = 0,04) y nuestro instrumento exploratorio ( p = 0,009), pero no en las puntuaciones funcionales medidas con los cuestionarios tradicionales. Adem&#xe1;s, la calidad de vida espec&#xed;fica de la condici&#xf3;n se correlacion&#xf3; fuertemente con la puntuaci&#xf3;n de gravedad del consenso Delphi (rs = -0,73).LIMITACIONES:Datos de una sola instituci&#xf3;n y tama&#xf1;o de muestra limitado.CONCLUSIONES:Las importantes prioridades identificadas por el consenso Delphi podr&#xed;an permitir una visi&#xf3;n global y una mejor evaluaci&#xf3;n del s&#xed;ndrome de resecci&#xf3;n anterior baja despu&#xe9;s de la resecci&#xf3;n interesfint&#xe9;rica. (Traducci&#xf3;n-Dr. Yesenia Rojas-Khalil ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, The Characteristic Medical Center of PLA Rocket Force, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuo</LastName><ForeName>Guang-Zuan</ForeName><Initials>GZ</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, The Characteristic Medical Center of PLA Rocket Force, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Fei-Fan</ForeName><Initials>FF</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, The Characteristic Medical Center of PLA Rocket Force, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Postgraduate Training Base of Jinzhou Medical University, The Characteristic Medical Center of PLA Rocket Force, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yu-Juan</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, The Characteristic Medical Center of PLA Rocket Force, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, The Characteristic Medical Center of PLA Rocket Force, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Jian-Bin</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Jian-Hua</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-0858-1941</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, The Characteristic Medical Center of PLA Rocket Force, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z211100002921044</GrantID><Agency>Clinical Research Fund of Beijing Municipal Science and Technology Commission</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094123" MajorTopicYN="N">Low Anterior Resection Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>10</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38305749</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003210</ArticleId><ArticleId IdType="pii">00003453-202405000-00017</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wrenn SM, Cepeda-Benito A, Ramos-Valadez DI, Cataldo PA. Patient perceptions and quality of life after colon and rectal surgery: what do patients really want? Dis Colon Rectum. 2018;61:971&#x2013;978.</Citation></Reference><Reference><Citation>Tsukamoto S, Miyake M, Shida D, Ochiai H, Yamada K, Kanemitsu Y. Intersphincteric resection has similar long-term oncologic outcomes compared with abdominoperineal resection for low rectal cancer without preoperative therapy: results of propensity score analyses. Dis Colon Rectum. 2018;61:1035&#x2013;1042.</Citation></Reference><Reference><Citation>Rouanet P, Rivoire M, Gourgou S, et al. Sphincter-saving surgery after neoadjuvant therapy for ultra-low rectal cancer where abdominoperineal resection was indicated: 10-year results of the GRECCAR 1 trial. Br J Surg. 2021;108:10&#x2013;13.</Citation></Reference><Reference><Citation>Rouanet P, Rivoire M, Gourgou S, et al. Sphincter-saving surgery for ultra-low rectal carcinoma initially indicated for abdominoperineal resection: is it safe on a long-term follow-up? J Surg Oncol. 2021;123:299&#x2013;310.</Citation></Reference><Reference><Citation>Collard M, Lefevre JH. Ultimate functional preservation with intersphincteric resection for rectal cancer. Front Oncol. 2020;10:297.</Citation></Reference><Reference><Citation>Zhang B, Zhao K, Zhao YJ, et al. Variation in rectoanal inhibitory reflex after laparoscopic intersphincteric resection for ultralow rectal cancer. Colorectal Dis. 2021;23:424&#x2013;433.</Citation></Reference><Reference><Citation>Annicchiarico A, Martellucci J, Solari S, Scheiterle M, Bergamini C, Prosperi P. Low anterior resection syndrome: can it be prevented? Int J Colorectal Dis. 2021;36:2535&#x2013;2552.</Citation></Reference><Reference><Citation>Marinello F, Pellino G, Esp&#xed;n-Basany E. Low anterior resection syndrome: an unavoidable price to pay to preserve the rectum? Front Oncol. 2022;12:994720.</Citation></Reference><Reference><Citation>Zhang B, Zhuo G-Z, Zhao Y, et al. Quality of life and functional outcomes after intersphincteric resection for ultralow rectal cancer: a prospective observational study. Dis Colon Rectum. 2023;66:1029&#x2013;1038.</Citation></Reference><Reference><Citation>Chen TY, Emmertsen KJ, Laurberg S. What are the best questionnaires to capture anorectal function after surgery in rectal cancer? Curr Colorectal Cancer Rep. 2015;11:37&#x2013;43.</Citation></Reference><Reference><Citation>Ribas Y, Aguilar F, Jovell-Fern&#xe1;ndez E, Cayetano L, Navarro-Luna A, Mu&#xf1;oz-Duyos A. Clinical application of the LARS score: results from a pilot study. Int J Colorectal Dis. 2017;32:409&#x2013;418.</Citation></Reference><Reference><Citation>Kiyozumi Y, Nagasaki T, Matsui S, et al. The evaluation of postoperative bowel dysfunction in Japanese patients with rectal cancer. Surg Today. 2023;53:596&#x2013;604.</Citation></Reference><Reference><Citation>Ito M, Saito N, Sugito M, Kobayashi A, Nishizawa Y, Tsunoda Y. Analysis of clinical factors associated with anal function after intersphincteric resection for very low rectal cancer. Dis Colon Rectum. 2009;52:64&#x2013;70.</Citation></Reference><Reference><Citation>Denost Q, Moreau JB, Vendrely V, et al. Intersphincteric resection for low rectal cancer: the risk is functional rather than oncological. A 25-year experience from Bordeaux. Colorectal Dis. 2020;22:1603&#x2013;1613.</Citation></Reference><Reference><Citation>Temple LKF. Expert commentary on low anterior resection syndrome. Dis Colon Rectum. 2019;62:1423&#x2013;1424.</Citation></Reference><Reference><Citation>Keane C, Fearnhead NS, Bordeianou LG, et al.; LARS International Collaborative Group. International consensus definition of low anterior resection syndrome. Dis Colon Rectum. 2020;63:274&#x2013;284.</Citation></Reference><Reference><Citation>Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993;36:77&#x2013;97.</Citation></Reference><Reference><Citation>Emmertsen KJ, Laurberg S; Rectal Cancer Function Study Group. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg. 2013;100:1377&#x2013;1387.</Citation></Reference><Reference><Citation>Rockwood TH, Church JM, Fleshman JW, et al. Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. Dis Colon Rectum. 2000;43:9&#x2013;16; discussion 16.</Citation></Reference><Reference><Citation>Hou XT, Pang D, Lu Q, et al. Validation of the Chinese version of the low anterior resection syndrome score for measuring bowel dysfunction after sphincter-preserving surgery among rectal cancer patients. Eur J Oncol Nurs. 2015;19:495&#x2013;501.</Citation></Reference><Reference><Citation>Mak TW, Leung WW, Ngo DK, Lee JFY, Hon SSF, Ng SSM. Translation and validation of the traditional Chinese version of the faecal incontinence quality of life scale. Int J Colorectal Dis. 2016;31:445&#x2013;450.</Citation></Reference><Reference><Citation>Keane C, Wells C, O&#x2019;Grady G, Bissett IP. Defining low anterior resection syndrome: a systematic review of the literature. Colorectal Dis. 2017;19:713&#x2013;722.</Citation></Reference><Reference><Citation>Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126:1763&#x2013;1768.</Citation></Reference><Reference><Citation>Kupsch J, Jackisch T, Matzel KE, et al. Outcome of bowel function following anterior resection for rectal cancer&#x2014;an analysis using the low anterior resection syndrome (LARS) score. Int J Colorectal Dis. 2018;33:787&#x2013;798.</Citation></Reference><Reference><Citation>Verkuijl SJ, Hoff C, Furn&#xe9;e EJB, et al. Anastomotic height is a valuable indicator of long-term bowel function following surgery for rectal cancer. Dis Colon Rectum. 2023;66:221&#x2013;232.</Citation></Reference><Reference><Citation>Zhang B, Zhuo GZ, Zhao K, et al. Cumulative incidence and risk factors of permanent stoma after intersphincteric resection for ultralow rectal cancer. Dis Colon Rectum. 2022;65:66&#x2013;75.</Citation></Reference><Reference><Citation>Martin ST, Heneghan HM, Winter DC. Systematic review of outcomes after intersphincteric resection for low rectal cancer. Br J Surg. 2012;99:603&#x2013;612.</Citation></Reference><Reference><Citation>Christensen P, Im Baeten C, Esp&#xed;n-Basany E, et al.; MANUEL Project Working Group. Management guidelines for low anterior resection syndrome - the MANUEL project. Colorectal Dis. 2021;23:461&#x2013;475.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36515515</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Surgical Management of Patients With GI Tuberculosis.</ArticleTitle><Pagination><StartPage>106</StartPage><EndPage>112</EndPage><MedlinePgn>106-112</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002626</ELocationID><Abstract><AbstractText Label="BACKGROUND">The Philippines ranks 10th in tuberculosis prevalence worldwide. Aside from pulmonary tuberculosis, GI tuberculosis remains an important cause of morbidity and mortality, particularly in endemic areas.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to describe the clinicopathologic profile and surgical outcomes of patients with GI tuberculosis.</AbstractText><AbstractText Label="DESIGN">Retrospective descriptive study.</AbstractText><AbstractText Label="SETTING">Department of Surgery at the Philippine General Hospital, Manila, Philippines.</AbstractText><AbstractText Label="PATIENTS">This study included all newly diagnosed cases of GI tuberculosis from January 1, 2009, to December 31, 2019.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Clinical response to surgery.</AbstractText><AbstractText Label="RESULTS">A total of 241 confirmed new cases were managed during an 11-year period. Of these, 208 patients (86.30%) underwent outright surgery, whereas the remaining patients (13.69%) received antituberculous therapy. Fifteen medically managed patients eventually required surgery, bringing the total surgically managed patients to 223. The patients' age ranged from 19 to 72 years, with a 1.9:1 male to female ratio. The most common complaint was abdominal pain. Intestinal obstruction was the most common indication for surgery. A right hemicolectomy was the most often performed procedure, with the ileocecal area as the most frequently involved segment. The most common histopathologic findings were epithelioid granuloma and caseation necrosis. Postoperative length of stay ranged from 0 to 59 days (mean, 7 days). Morbidity rate was 5.38% and mortality rate was 3.14%. Four deaths were operative and resulted from septic shock because of hollow viscus perforation.</AbstractText><AbstractText Label="LIMITATIONS">This study was limited to histopathologic basis for diagnosis.</AbstractText><AbstractText Label="CONCLUSION">The recommended initial therapy for all forms of extrapulmonary tuberculosis is a 6-month regimen of antituberculous therapy unless the organisms are known or suspected to be resistant to first-line drugs. Surgery is reserved for complications of intra-abdominal tuberculosis: obstruction, perforation, or severe bleeding. Timely surgical intervention, coupled with medical management led to the best outcomes for these patients. See Video Abstract at http://links.lww.com/DCR/C56.</AbstractText><AbstractText Label="MANEJO QUIRRGICO DE PACIENTES CON TUBERCULOSIS GASTROINTESTINAL">ANTECEDENTES:Las Filipinas ocupa el d&#xe9;cimo lugar en prevalencia de tuberculosis en todo el mundo. Aparte de la tuberculosis pulmonar, la tuberculosis gastrointestinal sigue siendo una causa importante de morbilidad y mortalidad, especialmente en las zonas end&#xe9;micas.OBJETIVO:Este estudio tuvo como objetivo describir el perfil clinicopatol&#xf3;gico y los resultados quir&#xfa;rgicos de pacientes con tuberculosis gastrointestinal.DISE&#xd1;O:Estudio descriptivo retrospectivo.AJUSTE:Departamento de Cirug&#xed;a del Hospital General de Filipinas, Manila, Filipinas.PACIENTES:Todos los casos de tuberculosis gastrointestinal reci&#xe9;n diagnosticados desde el 1 de Enero del 2009 hasta el 31 de Diciembre del 2019.MEDIDAS DE RESULTADO PRINCIPAL:Respuesta cl&#xed;nica a la cirug&#xed;a.RESULTADOS:Se manejaron un total de 241 casos nuevos confirmados durante un per&#xed;odo de 11 a&#xf1;os. De estos, 208 (86,30%) pacientes fueron intervenidos directamente quir&#xfa;rgicamente mientras que el resto recibi&#xf3; tratamiento antituberculoso (13,69%). Quince pacientes manejados m&#xe9;dicamente finalmente requirieron cirug&#xed;a, lo que elev&#xf3; el total de pacientes manejados quir&#xfa;rgicamente a 223. Las edades de los pacientes oscilaron entre 19 y 72 a&#xf1;os, con una proporci&#xf3;n de 1,9: 1 entre hombres y mujeres. La queja m&#xe1;s com&#xfa;n fue el dolor abdominal. La obstrucci&#xf3;n intestinal fue la indicaci&#xf3;n m&#xe1;s frecuente para cirug&#xed;a. La hemicolectom&#xed;a derecha fue el procedimiento m&#xe1;s realizado, siendo la zona ileocecal el segmento m&#xe1;s afectado. Los hallazgos histopatol&#xf3;gicos m&#xe1;s comunes fueron granuloma epitelioide y necrosis caseosa. La estancia postoperatoria vari&#xf3; de 0 a 59 d&#xed;as (media, 7 d&#xed;as). Las tasas de morbilidad y mortalidad fueron 5,38% y 3,14%, respectivamente. Cuatro fueron muertes operatorias por choque s&#xe9;ptico debido a perforaci&#xf3;n de v&#xed;scera.LIMITACIONES:Este estudio se limit&#xf3; a la base histopatol&#xf3;gica para el diagn&#xf3;stico.CONCLUSI&#xd3;N:La terapia inicial recomendada para todas las formas de tuberculosis extrapulmonar es un r&#xe9;gimen de 6 meses de terapia antituberculosa a menos que se sepa o se sospeche que los organismos son resistentes a los medicamentos de primera l&#xed;nea. La cirug&#xed;a se reserva para las complicaciones de la tuberculosis intraabdominal, es decir, obstrucci&#xf3;n, perforaci&#xf3;n o hemorragia grave. La intervenci&#xf3;n quir&#xfa;rgica oportuna, junto con el manejo m&#xe9;dico, condujo a mejores resultados para estos pacientes. Consulte el Resumen del Video en http://links.lww.com/DCR/C56. (Traducci&#xf3;n- Dr. Yesenia Rojas-Khalil).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Limpin</LastName><ForeName>Emmanuel T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Department of Surgery, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Marc Paul J</ForeName><Initials>MPJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maglangit</LastName><ForeName>Sittie Aneza Camille A</ForeName><Initials>SACA</Initials><AffiliationInfo><Affiliation>Department of Surgery, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Joshua Josef R</ForeName><Initials>JJR</Initials><AffiliationInfo><Affiliation>Section of Gastroenterology, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onglao</LastName><ForeName>Mark Augustine S</ForeName><Initials>MAS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabanilla-Manuntag</LastName><ForeName>Ma Corazon</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maralit</LastName><ForeName>Ruter M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Section of Gastroenterology, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dofitas</LastName><ForeName>Rodney B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Surgery, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010679" MajorTopicYN="N" Type="Geographic">Philippines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="Y">Tuberculosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36515515</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002626</ArticleId><ArticleId IdType="pii">00003453-202301000-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Global Tuberculosis Report 2020. Geneva, Switzerland: World Health Organization; 2020. https:// www.who.int/tb/publications/global_report/en . Accessed February 4, 2020.</Citation></Reference><Reference><Citation>Jain A. Extra pulmonary tuberculosis: a diagnostic dilemma. Indian J Clin Biochem. 2011;26:269&#x2013;273.</Citation></Reference><Reference><Citation>Colon F. Extrapulmonary tuberculosis: 21 patients at Western Visayas Medical Center DOTS Clinic, Philippines (January 2016 to December 2017). e-Learning resources. https://erj.ersjournals.com/content/52/suppl_62/PA2754 . Published 2018. Accessed February 4, 2020.</Citation></Reference><Reference><Citation>Chakinala RC, Farkas ZC, Barbash B, et al. Gastrointestinal tuberculosis presenting as malnutrition and distal colonic bowel obstruction. Case Rep Gastro Med. 2018;2018;2808565.</Citation></Reference><Reference><Citation>Awasthi S, Saxena M, Ahmad F, Kumar A, Dutta S. Abdominal tuberculosis: a diagnostic dilemma. J Clin Diagn Res. 2015;9:EC01&#x2013;EC03.</Citation></Reference><Reference><Citation>Malikowski T, Mahmood M, Smyrk T, Raffals L, Nehra V. Tuberculosis of the gastrointestinal tract and associated viscera. J Clin Tuberc Other Mycobact Dis. 2018;12:1&#x2013;8.</Citation></Reference><Reference><Citation>Kasulke RJ, Anderson WJ, Gupta SK, Gliedman ML. Primary tuberculous enterocolitis. Report of three cases and review of literature. Arch Surg. 1981;116:110&#x2013;13.</Citation></Reference><Reference><Citation>Tam CM, Leung CC, Noertjojo K, Chan SL, Chan-Yeung M. Tuberculosis in Hong Kong&#x2014;patient characteristics and treatment outcome. Hong Kong Med J. 2003;9:83&#x2013;90.</Citation></Reference><Reference><Citation>Task Force: Clinical Practice Guidelines for the Diagnosis, Treatment, Prevention and Control of Tuberculosis in Adult Filipinos: 2016 Update (CPGTB2016). Philippine Coalition Against Tuberculosis (PhilCAT), Philippine Society for Microbiology and Infectious Diseases (PSMID), Philippine College of Chest Physicians (PCCP). Available from: https://pcp.org.ph/index.php/membership/benefits/application-forms/341-psbim/1041-psbim-guidelines-2020 . Accessed February 4, 2020.</Citation></Reference><Reference><Citation>Vianzon R, Garfin AM, Lagos A, Belen R. The tuberculosis profile of the Philippines, 2003-2011: advancing DOTS and beyond. Western Pac Surveill Response J. 2013;4:11&#x2013;16.</Citation></Reference><Reference><Citation>Debi U, Ravisankar V, Prasad KK, Sinha SK, Sharma AK. Abdominal tuberculosis of the gastrointestinal tract: revisited. World J Gastroenterol. 2014;20:14831&#x2013;14840.</Citation></Reference><Reference><Citation>Khanna V, Kummar A, Alexander N, Surendran P. Case report on esophageal tuberculosis&#x2014;a rare entity. Int J Surg Case Rep. 2017;35:41&#x2013;43.</Citation></Reference><Reference><Citation>Sreeramareddy CT, Panduru KV, Verma SC, Joshi HS, Bates MN. Comparison of pulmonary and extrapulmonary tuberculosis in Nepal&#x2014;a hospital-based retrospective study. BMC Infect Dis. 2008;8:8.</Citation></Reference><Reference><Citation>Choi EH, Coyle WJ. Gastrointestinal tuberculosis. Microbiol Spectr. 2016;4. doi: 10.1128/microbiolspec.TNMI7-0014-2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/microbiolspec.TNMI7-0014-2016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennette MD. Principles and Practice of Infectious Disease. 8th ed. Philadelphia: Saunders; 2015; 1263&#x2013;1269.</Citation></Reference><Reference><Citation>Al-Bahrani ZR, Al-Saleem T. Intestinal tuberculosis in Iraq: a study of 50 cases. Int Surg. 1982;67(suppl):483&#x2013;485.</Citation></Reference><Reference><Citation>Gilinsky NH, Marks IN, Kottler RE, Price SK. Abdominal tuberculosis. A 10-year review. S Afr Med J. 1983;64:849&#x2013;857.</Citation></Reference><Reference><Citation>Sharma V, Nath P. Tuberculosis of the Gastrointestinal System. Singapore: Springer Nature Singapore Pte Ltd; 2022.</Citation></Reference><Reference><Citation>Seth AK, Nijhawan VS, Bhandari MK, Dhaka RS, Kochar SK. Gastric tuberculosis: a case report. Med J Armed Forces India. 1998;54:278&#x2013;279.</Citation></Reference><Reference><Citation>Ramirez-Lapausa M, Menendez-Saldana A, Noguerado-Asensio A. Extrapulmonary tuberculosis: an overview. Rev Esp Sanid Penit. 2015;17:3&#x2013;11.</Citation></Reference><Reference><Citation>Rajbhandari R, Blakemore S, Gupta N, et al. Crohn&#x2019;s disease in low and lower-middle income countries: a scoping review. World J Gastroenterol. 2020;26:6891&#x2013;6908.</Citation></Reference><Reference><Citation>Ye Z, Lin Y, Cao Q, He Y, Xue L. Granulomas as the most useful histopathological feature in distinguishing between Crohn&#x2019;s disease and intestinal tuberculosis in endoscopic biopsy specimens. Medicine (Baltimore). 2015;94:e2157.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34775415</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Outcomes of Patients With Local Regrowth After Nonoperative Management of Rectal Cancer After Neoadjuvant Chemoradiotherapy.</ArticleTitle><Pagination><StartPage>333</StartPage><EndPage>339</EndPage><MedlinePgn>333-339</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002197</ELocationID><Abstract><AbstractText Label="BACKGROUND">Clinical complete responders after chemoradiation for rectal cancer are increasingly being managed by a watch-and-wait strategy. Nonetheless, a significant proportion will experience a local regrowth, and the long-term oncological outcomes of these patients is not totally known.</AbstractText><AbstractText Label="OBJECTIVE">The purpose of this study was to analyze the outcomes of patients who submitted to a watch-and-wait strategy and developed a local regrowth, and to compare these results with sustained complete clinical responders.</AbstractText><AbstractText Label="DESIGN">This was a retrospective study.</AbstractText><AbstractText Label="SETTING">Single institution, tertiary cancer center involved in alternatives to organ preservation.</AbstractText><AbstractText Label="PATIENTS">Patients with a biopsy-proven rectal adenocarcinoma (stage II/III or low lying cT2N0M0 at risk for an abdominoperineal resection) treated with chemoradiation who were found at restage to have a clinical complete response.</AbstractText><AbstractText Label="INTERVENTIONS">Rectal cancer patients treated with chemoradiation who underwent a watch-and-wait strategy (without a full thickness local excision) and developed a local regrowth were compared to the remaining patients of the watch-and-wait strategy.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Overall survival between groups, incidence of regrowth' and results of salvage surgery.</AbstractText><AbstractText Label="RESULTS">There were 67 patients. Local regrowth occurred in 20 (29.9%) patients treated with a watch-and-wait strategy. Mean follow-up was 62.7 months. Regrowth occurred at mean 14.2 months after chemoradiation, half of them within the first 12 months. Patients presented with comparable initial staging, lateral pelvic lymph-node metastasis, and extramural venous invasion. The regrowth group had a statistically nonsignificant higher incidence of mesorectal fascia involvement (35.0% vs 13.3%, p = 0.089). All regrowths underwent salvage surgery, mostly (75%) a sphincter-sparing procedure. 5-year overall survival was 71.1% in patients with regrowth and 91.1% in patients with a sustained complete clinical response (p = 0.027).</AbstractText><AbstractText Label="LIMITATIONS">This study was limited by its retrospective evaluation of patient selection for a watch-and-wait strategy and outcomes, as well as its small sample size.</AbstractText><AbstractText Label="CONCLUSIONS">Local regrowth is a frequent event when following a watch-and-wait policy (29.9%); however, patients could undergo salvage surgical treatment with adequate pelvic control. In this series, overall survival showed a statistically significant difference from patients managed with a watch-and-wait strategy who experienced a local regrowth compared to those who did not. See Video Abstract at http://links.lww.com/DCR/B773.RESULTADOS DE LOS PACIENTES CON REBROTE LOCAL, DESPU&#xc9;S DEL MANEJO NO QUIR&#xda;RGICO DEL C&#xc1;NCER DE RECTO, DESPU&#xc9;S DE LA QUIMIORRADIOTERAPIA NEOADYUVANTEANTECEDENTES:Los respondedores cl&#xed;nicos completos, despu&#xe9;s de la quimiorradiaci&#xf3;n para el c&#xe1;ncer de recto, se tratan cada vez m&#xe1;s mediante una estrategia de observaci&#xf3;n y espera. No obstante, una proporci&#xf3;n significativa experimentar&#xe1; un rebrote local y los resultados oncol&#xf3;gicos a largo plazo de estos pacientes, no se conocen por completo.OBJETIVO:El prop&#xf3;sito de este estudio, fue analizar los resultados de los pacientes sometidos a una estrategia de observaci&#xf3;n y espera, que desarrollaron un rebrote local, y comparar estos resultados con respondedores cl&#xed;nicos completos sostenidos.DISE&#xd1;O:Este fue un estudio retrospectivo.ENTORNO CLINICO.Instituci&#xf3;n &#xfa;nica, centro oncol&#xf3;gico terciario involucrado en alternativas a la preservaci&#xf3;n de &#xf3;rganos.PACIENTES:Pacientes con un adenocarcinoma de recto comprobado por biopsia (estadio II / III o posici&#xf3;n baja cT2N0M0, en riesgo de resecci&#xf3;n abdominoperineal), tratados con quimiorradiaci&#xf3;n, y que durante un reestadiaje, presentaron una respuesta cl&#xed;nica completa.INTERVENCIONES:Los pacientes con c&#xe1;ncer de recto tratados con quimiorradiaci&#xf3;n, sometidos a una estrategia de observaci&#xf3;n y espera (sin una escisi&#xf3;n local de espesor total) y que desarrollaron un rebrote local, se compararon con los pacientes restantes de la estrategia de observaci&#xf3;n y espera.PRINCIPALES MEDIDAS DE VALORACION:Supervivencia global entre los grupos, incidencia de rebrote y resultados de la cirug&#xed;a de rescate.RESULTADOS:Fueron 67 pacientes. El rebrote local ocurri&#xf3; en 20 (29,9%) pacientes tratados con una estrategia de observaci&#xf3;n y espera. El seguimiento medio fue de 62,7 meses. El rebrote se produjo a la media de 14,2 meses despu&#xe9;s de la quimiorradiaci&#xf3;n, la mitad de ellos dentro de los primeros 12 meses. Los pacientes se presentaron con una estadificaci&#xf3;n inicial comparable, met&#xe1;stasis en los ganglios linf&#xe1;ticos p&#xe9;lvicos laterales e invasi&#xf3;n venosa extramural. El grupo de rebrote tuvo una mayor incidencia estad&#xed;sticamente no significativa de afectaci&#xf3;n de la fascia mesorrectal (35,0 vs 13,3%, p = 0,089). Todos los rebrotes se sometieron a cirug&#xed;a de rescate, en su mayor&#xed;a (75%) con procedimiento de preservaci&#xf3;n del esf&#xed;nter. La supervivencia global a 5 a&#xf1;os fue del 71,1% en pacientes con rebrote y del 91,1% en pacientes con una respuesta cl&#xed;nica completa sostenida (p = 0,027).LIMITACIONES:Evaluaci&#xf3;n retrospectiva de la selecci&#xf3;n de pacientes para una estrategia y resultados de observar y esperar, tama&#xf1;o de muestra peque&#xf1;o.CONCLUSIONES:El rebrote local es un evento frecuente despu&#xe9;s de la pol&#xed;tica de observaci&#xf3;n y espera (29,9%), sin embargo los pacientes podr&#xed;an someterse a un tratamiento quir&#xfa;rgico de rescate con un adecuado control p&#xe9;lvico. En esta serie, la supervivencia global mostr&#xf3; una diferencia estad&#xed;sticamente significativa de los pacientes manejados con una estrategia de observaci&#xf3;n y espera que experimentaron un rebrote local, en comparaci&#xf3;n con los que no lo hicieron. Consulte Video Resumen en http://links.lww.com/DCR/B773. (Traducci&#xf3;n-Dr. Fidel Ruiz Healy).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cotti</LastName><ForeName>Guilherme Cutait</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Surgical Division, University of S&#xe3;o Paulo Medical School, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandini</LastName><ForeName>Rafael Vaz</ForeName><Initials>RV</Initials></Author><Author ValidYN="Y"><LastName>Braghiroli</LastName><ForeName>Oddone F M</ForeName><Initials>OFM</Initials></Author><Author ValidYN="Y"><LastName>Nahas</LastName><ForeName>Caio S R</ForeName><Initials>CSR</Initials></Author><Author ValidYN="Y"><LastName>Bustamante-Lopez</LastName><ForeName>Leonardo A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Marques</LastName><ForeName>Carlos Frederico S</ForeName><Initials>CFS</Initials></Author><Author ValidYN="Y"><LastName>Imperiale</LastName><ForeName>Antonio R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>Ullysses</ForeName><Initials>U</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Salvajoli</LastName><ForeName>Bernardo</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Hoff</LastName><ForeName>Paulo M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Nahas</LastName><ForeName>Sergio C</ForeName><Initials>SC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2022 Oct 1;65(10):e963. doi: 10.1097/DCR.0000000000002519.</RefSource><PMID Version="1">35671257</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2022 Oct 1;65(10):e962. doi: 10.1097/DCR.0000000000002518.</RefSource><PMID Version="1">35671258</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072700" MajorTopicYN="N">Conservative Treatment</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="Y">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059351" MajorTopicYN="Y">Organ Sparing Treatments</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057832" MajorTopicYN="N">Watchful Waiting</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>14</Day><Hour>21</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34775415</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002197</ArticleId><ArticleId IdType="pii">00003453-202203000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Habr-Gama A, de Souza PM, Ribeiro U Jr, et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum. 1998;41:1087&#x2013;1096.</Citation></Reference><Reference><Citation>Smith JJ, Strombom P, Chow OS, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5:e185896.</Citation></Reference><Reference><Citation>Habr-Gama A, S&#xe3;o Juli&#xe3;o GP, Perez RO. Nonoperative management of rectal cancer: identifying the ideal patients. Hematol Oncol Clin North Am. 2015;29:135&#x2013;151.</Citation></Reference><Reference><Citation>Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633&#x2013;4640.</Citation></Reference><Reference><Citation>Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:501&#x2013;513.</Citation></Reference><Reference><Citation>Dattani M, Heald RJ, Goussous G, et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg. 2018;268:955&#x2013;967.</Citation></Reference><Reference><Citation>Chadi SA, Malcomson L, Ensor J, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:825&#x2013;836.</Citation></Reference><Reference><Citation>Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53:1692&#x2013;1698.</Citation></Reference><Reference><Citation>Battersby N, Glasbey J, Neary P, et al.; 2017 European Society of Coloproctology (ESCP) collaborating group. Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral of surgery. Colorectal Dis. 2018;20(suppl 6):58&#x2013;68.</Citation></Reference><Reference><Citation>Maas M, Lambregts DM, Nelemans PJ, et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol. 2015;22:3873&#x2013;3880.</Citation></Reference><Reference><Citation>Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF, et al. Pathologic complete response in rectal cancer: can we detect it? lessons learned from aproposed randomized trial of watch-and-wait treatment of rectal cancer. Dis Colon Rectum. 2016;59:255&#x2013;263.</Citation></Reference><Reference><Citation>Martens MH, Maas M, Heijnen LA, et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst. 2016;108:djw171.</Citation></Reference><Reference><Citation>van der Valk MJM, Hilling DE, Bastiaannet E, et al.; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch &amp; Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537&#x2013;2545.</Citation></Reference><Reference><Citation>Habr-Gama A, Gama-Rodrigues J, S&#xe3;o Juli&#xe3;o GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014;88:822&#x2013;828.</Citation></Reference><Reference><Citation>Kong JC, Guerra GR, Warrier SK, Ramsay RG, Heriot AG. Outcome and salvage surgery following &#x201c;watch and wait&#x201d; for rectal cancer after neoadjuvant therapy: a systematic review. Dis Colon Rectum. 2017;60:335&#x2013;345.</Citation></Reference><Reference><Citation>Appelt AL, Pl&#xf8;en J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919&#x2013;927.</Citation></Reference><Reference><Citation>Habr-Gama A, S&#xe3;o Juli&#xe3;o GP, Vailati BB, et al. Organ preservation among patients with clinically node-positive rectal cancer: is it really more dangerous? Dis Colon Rectum. 2019;62:675&#x2013;683.</Citation></Reference><Reference><Citation>Yuval JB, Thompson HM, Garcia-Aguilar J. Organ preservation in rectal cancer. J Gastrointest Surg. 2020;24:1880&#x2013;1888.</Citation></Reference><Reference><Citation>Garcia-Aguilar J, et al. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. J Clin Oncol 2020;38:(suppl; abstr 4008)</Citation></Reference><Reference><Citation>Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17:174&#x2013;183.</Citation></Reference><Reference><Citation>Fernandez LM, Figueiredo NL, Habr-Gama A, et al. Salvage surgery with organ preservation for patients ith local regrowth after watch and wait: is it still possible? Dis Colon Rectum. 2020;63:1053&#x2013;1062.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34352864</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2444-054X</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>4</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Cirugia y cirujanos</Title><ISOAbbreviation>Cir Cir</ISOAbbreviation></Journal><ArticleTitle>Perfusi&#xf3;n aislada de extremidad: una opci&#xf3;n terap&#xe9;utica para met&#xe1;stasis en tr&#xe1;nsito de melanoma nodular y lentiginoso acral.</ArticleTitle><Pagination><StartPage>469</StartPage><EndPage>475</EndPage><MedlinePgn>469-475</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/CIRU.20000549</ELocationID><Abstract><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">describir la experiencia inicial en Colombia en el manejo del melanoma de extremidad con perfusi&#xf3;n aislada y comparar la respuesta de los subtipos histol&#xf3;gicos m&#xe1;s frecuentes en Colombia con la literatura.</AbstractText><AbstractText Label="MATERIALES Y M&#xc9;TODOS" NlmCategory="UNASSIGNED">estudio descriptivo, retrospectivo de una serie de pacientes con diagn&#xf3;stico de melanoma con met&#xe1;stasis en tr&#xe1;nsito tratados con perfusi&#xf3;n aislada de extremidad, seleccionados entre 2007 y 2016. Las variables cualitativas se analizaron con frecuencias absolutas y relativas. Las cuantitativas con medidas de tendencia central y dispersi&#xf3;n.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">11 pacientes fueron tratados con perfusi&#xf3;n aislada de extremidad. Hubo respuesta parcial en siete pacientes (63,6%), enfermedad estable en dos pacientes (18,2%) y progresi&#xf3;n en dos pacientes (18,2%). Despu&#xe9;s del tratamiento, cinco pacientes (45,5%) presentaron complicaciones menores.</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="CONCLUSIONS">la perfusi&#xf3;n aislada sigue siendo importante para el tratamiento del melanoma localmente avanzado con el fin de mejorar la calidad de vida de los pacientes. La respuesta puede cambiar seg&#xfa;n el tipo cl&#xed;nico de melanoma, siendo menor, seg&#xfa;n este estudio, en pacientes con melanoma lentiginoso acral y nodular, aunque por el bajo poder, esto no se puede concluir.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">to describe the initial experience in Colombia of locally advanced melanoma treated by isolated limb perfusion and compare the response rate of our melanoma subtypes with the literature.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">descriptive, retrospective study of a series of patients selected between 2007 and 2016. Qualitative variables were analyzed with proportions and frequencies, and quantitative variable with central tendency measures and measures of dispersion.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">11 patients were treated by isolated limb perfusion. After the treatment, seven patients (63.6%) had partial response, two patients (18.2%) had stable disease and two patients (18.2%) had disease progression. Five patients (45.5%) had mild complications.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Isolated limb perfusion is still an important treatment strategy for locally advanced melanoma, with the goal of improving the patient quality of life. The response can change according to the type of melanoma, and could be smaller in patients with acral lentiginous and nodular melanoma, although we cannot make this conclusion with this type of study because it has low power and lack of a comparison group.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2021 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duarte</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Seno y Tejidos Blandos, Instituto Nacional de Cancerolog&#xed;a, ESE, Asociaci&#xf3;n Colombiana de Mastolog&#xed;a, Universidad del Rosario, Universidad Militar Nueva Granada, Bogot&#xe1;. Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Restrepo</LastName><ForeName>Juliana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a Oncol&#xf3;gica. Instituto Nacional de Cancerolog&#xed;a, ESE, Universidad Militar Nueva Granada, Bogot&#xe1;. Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez</LastName><ForeName>Alden Pool</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a Oncol&#xf3;gica. Hospital Universitario del Valle, Universidad del Valle, Cali. Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carre&#xf1;o</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grupo de Investigaci&#xf3;n Cl&#xed;nica. Instituto Nacional de Cancerolog&#xed;a, ESE, Bogot&#xe1;. Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Isolated limb perfusion: A therapeutic option for nodular and acral lentiginous melanoma.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Cir Cir</MedlineTA><NlmUniqueID>0372736</NlmUniqueID><ISSNLinking>0009-7411</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Chemotherapy</Keyword><Keyword MajorTopicYN="N">C&#xe1;ncer</Keyword><Keyword MajorTopicYN="N">Limb salvage</Keyword><Keyword MajorTopicYN="N">Melanoma</Keyword><Keyword MajorTopicYN="N">Perfusi&#xf3;n regional</Keyword><Keyword MajorTopicYN="N">Quimioterapia</Keyword><Keyword MajorTopicYN="N">Regional perfusion</Keyword><Keyword MajorTopicYN="N">Salvamento de extremidad</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>5</Day><Hour>20</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34352864</ArticleId><ArticleId IdType="doi">10.24875/CIRU.20000549</ArticleId><ArticleId IdType="pii">j89/4/469</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>